Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...

Cambridge biotech company Mestag Therapeutics has appointed experienced executive Dr Matthew Sleeman as Chief Scientific ...

Avoiding surgery for rectal cancer, Sarah Rack of Memphis traveled to Houston for treatment every three weeks for 18 months.

Purple Biotech's growing intellectual property portfolio for NT219 in combination with anti-cancer standard-of-care therapies ...

Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment in ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

In a small study in a community oncology practice, more than 60% of patients with advanced squamous cell skin cancer treated ...

DelveInsight's Interferons Market Insights report provides the current and forecast market analysis, individual leading ...

Biosciences announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and ...

Mestag Therapeutics, a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease ...

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of ...